Aligos Therapeutics Inc (ALGS) USD0.0001
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics to address unmet medical needs in viral infections and liver diseases. It uses its small molecule and oligonucleotide platforms to develop pharmacologically optimized drug candidates for use in combination regimens. Its primary area of focus is on developing functional cure for nonalcoholic steatohepatitis (NASH) and to develop drug candidates with coronavirus activity, as well as seeks to enhance the rate of functional cure for chronic hepatitis B (CHB). It has developed a portfolio of differentiated drug candidates for CHB, including a small molecule capsid assembly modulator (CAM-E) and oligonucleotide small interfering ribonucleic acids (siRNA), each of which is designed against clinically validated targets in the hepatitis B virus (HBV) life cycle. Its pipeline includes ALG-055009 for the treatment of NASH; ALG-000184 and ALG-125755 for CHB, and ALG-097558 for coronavirus.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.